Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, . Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...

Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...

Please complete this form to contact Sanofi Canada. All information you provide will be maintained in accordance with our privacy policy. We provide product information and cannot offer medical advice ...

Parfois, l’innovation technologique peut provenir d’espace inattendus. Dans le développement de médicaments, cela signifie souvent l’intersection de technologies apparemment sans rapport ou de ...

100% of developing countries work towards the UNFCCC goal of having their NAPs in place by 2025, with all new NAPs including specific health targets reflecting national and sub-national priorities.

Hemophilia can affect nearly every aspect of a person’s life, but these daily impacts are often overlooked, and current solutions rarely go beyond medical care. Sanofi is committed to working with the ...

Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...

100 % des pays en développement œuvrent pour atteindre l'objectif de la CCNUCC d'avoir leurs PNA (Plans nationaux d'adaptation) en place d'ici 2025, avec l'inclusion dans chaque nouveau PNA ...